We were able to recommend targeted and personalized treatment for 11 patients; KCNT1-related epilepsy (No. 44) quinidine has been used as an off-label anticonvulsant (13, 14), molybdenum cofactor deficiency type A (No. 64) with cyclic pyranopterin monophosphate (cPMP) (15),Succinic semialdehyde dehydrogenase deficiency (No. 41) with vigabatrin (16), cerebral creatin deficiency (No. 39) with creatin monophosphate (17), WWOX gene mutation (N0. Here, KCNT1 is linked to succinic semialdehyde dehydrogenase deficiency.